Akèy › Kansè pankreyas › Oklahoma › Oklahoma City
Etid klinik pou Kansè pankreyas nan Oklahoma City, OK
11 etid pou Kansè pankreyas ap chèche patisipan nan sit nan ak bò kote Oklahoma City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Ap rekriteFaz 3
- Mercy Hospital Oklahoma City - Mercy Coletta Cancer Center - Oklahoma City, Oklahoma City
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- University of Oklahoma, Oklahoma City
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Ap rekriteEtid obsèvasyon
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Ap rekriteFaz 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Ap rekriteFaz 2
- Hightower Clinical, Oklahoma City
ctDNA Assay in Patients With Resectable Pancreatic Cancer
Ap rekriteEtid obsèvasyon
- University of Oklahoma, Oklahoma City
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ap rekriteFaz 2
- Ohio State University-Telemedicine, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #13, Oklahoma City
Etid Kansè pankreyas nan lòt vil
- Houston, TX61 etid
- New York City, NY60 etid
- Boston, MA43 etid
- Nashville, TN39 etid
- Los Angeles, CA35 etid
- St. Louis, MO33 etid
- Arlington, VA33 etid
- Baltimore, MD31 etid
- San Antonio, TX31 etid
- Philadelphia, PA26 etid
- Tampa, FL26 etid
- Durham, NC24 etid
Lòt etid nan Oklahoma City
- Kansè Poumon ki pa ti selil28 etid
- Kansè ovè28 etid
- Kansè Endomèt25 etid
- Kansè kolorektal22 etid
- Kansè pwostat21 etid
- Kansè poumon19 etid
- Kansè nan tete17 etid
- Kansè Metastatik16 etid
- Kansè (tout kalite)14 etid
- Leksemi mieloïd egi14 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Kansè vejik11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.